Marshall Wace North America’s NextCure NXTC Stock Holding History

Marshall Wace North America’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$261K	Sell	3,227 -266	-8%	-$23.3K	﹤0.01%	1280
2021 Q2	$337K	Sell	3,493 -10,114	-74%	-$1.03M	﹤0.01%	1259
2021 Q1	$1.64M	Sell	13,607 -533	-4%	-$77.2K	0.01%	886
2020 Q4	$1.85M	Buy	14,140 +8,125	+135%	+$1.05M	0.01%	776
2020 Q3	$634K	Buy	6,015 +261	+5%	+$32.1K	﹤0.01%	914
2020 Q2	$1.48M	Sell	5,754 -14,159	-71%	-$5.39M	0.01%	657
2020 Q1	$8.86M	Buy	19,913 +7,123	+56%	+$3.8M	0.07%	236
2019 Q4	$8.64M	Buy	+12,790	New	+$6.42M	0.04%	314

Other funds holding NXTC

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marshall Wace North America's NXTC Position: Q3 2021 in Review

Marshall Wace North America reduced its NextCure (NXTC) stake by 7.6% in Q3 2021, selling an estimated $23.3K and leaving 3,227 shares worth $261K. The position accounts for ﹤0.01% of the portfolio, ranked #1280.

Marshall Wace North America first reported a position in NXTC in Q4 2019 and has held it in 8 quarters since. The position peaked at $8.86M in Q1 2020. 71 funds tracked by Wall St. Rank hold NXTC as of Q3 2021.

Marshall Wace North America held 3,227 shares of NextCure worth $261K as of Q3 2021.
Marshall Wace North America sold 266 NextCure shares in Q3 2021, an estimated $23.3K.
NextCure made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #1280 holding.
Marshall Wace North America first reported a position in NextCure in Q4 2019 and has held it in 8 quarters since.
Marshall Wace North America's NextCure position peaked at $8.86M in Q1 2020.
71 funds tracked by Wall St. Rank held NextCure as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.